Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GoodRx HoldingsGDRX +0.64%70 EV-to-EBITDA is 8.66 as of Aug. 13, 2026, which is 59% below its 10-year median of 21.10. GuruFocus rates GDRX with a GF Score™ of 70/100 and a GF Value™ of $5.26 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 512 Healthcare Providers & Services companies, GoodRx Holdings ranks better than 62.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, GoodRx Holdings's enterprise value is $1,478.8 Mil.
GoodRx Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $170.8 Mil. Therefore, GoodRx Holdings's EV-to-EBITDA for today is 8.66.
The historical rank and industry rank for GoodRx Holdings's EV-to-EBITDA or its related term are showing as below:
GDRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -86.55 Med: 21.1 Max: 276.94
Current: 8.66
During the past 8 years, the highest EV-to-EBITDA of GoodRx Holdings was 276.94. The lowest was -86.55. And the median was 21.10.
GDRX's EV-to-EBITDA is ranked better than 62.3% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.835
vs GDRX: 8.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GoodRx Holdings's PE Ratio (TTM) for today is calculated as:
GoodRx Holdings's share price for today is $3.623.
GoodRx Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for GoodRx Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, GoodRx Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GoodRx Holdings EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, GoodRx Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GoodRx Holdings's EV-to-EBITDA falls into.
GoodRx Holdings's current Enterprise Value is $1,478.8 Mil.
GoodRx Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $170.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GoodRx Holdings (GDRX) has a EV-to-EBITDA of 8.66 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GoodRx Holdings. This is 59% below median its historical median of 21.10. According to the industry distribution chart, GoodRx Holdings ranks #193 out of 512 companies in the Healthcare Providers & Services industry, placing it in the top 37.7%.
Is GoodRx Holdings' EV-to-EBITDA too high?
GoodRx Holdings' current EV-to-EBITDA of 8.66 is 59% below median its 10-year median of 21.10. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.84. GoodRx Holdings' value of 8.66 is 20.1% below this industry median. Based on the distribution chart, GoodRx Holdings ranks #193 out of 512 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, GoodRx Holdings has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GoodRx Holdings' EV-to-EBITDA compare to SDGR and TALK?
According to the Healthcare Providers & Services industry distribution chart, GoodRx Holdings ranks #193 out of 512 companies for EV-to-EBITDA. This puts GoodRx Holdings in the upper half of its industry. The industry median EV-to-EBITDA is 10.84. GoodRx Holdings' value of 8.66 is 20.1% below this benchmark. While the company's 10-year median is 21.10 vs. the industry median of 10.84, GoodRx Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.84, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GoodRx Holdings's current EV-to-EBITDA of 8.66 is 20.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GoodRx Holdings. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GoodRx Holdings's current EV-to-EBITDA is 8.66, which is 59% below median its own 10-year median of 21.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GoodRx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GoodRx Holdings (GDRX) is currently considered Possible Value Trap. The stock's GF Value™ is $5.26, compared to a current price of $3.62 — trading 31.1% below its estimated fair value. The current EV-to-EBITDA is 8.66, which is 59% below median its 10-year median of 21.10 and 20.1% below the Healthcare Providers & Services industry median of 10.84. GoodRx Holdings' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For GoodRx Holdings (GDRX), the current EV-to-EBITDA is 8.66 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GoodRx Holdings (GDRX) Overvalued in 2026?
Based on GuruFocus' analysis, GoodRx Holdings stock appears to be undervalued.
The current stock price of $3.62 is trading 31.1% below its estimated GF Value™ of $5.26.
GuruFocus considers GoodRx Holdings to be Possible Value Trap.
Key valuation signals for GDRX:
EV-to-EBITDA: 8.66 (59% below median its 10-year median of 21.10)
GF Value™: $5.26 vs. price of $3.62 (31.1% below fair value)
Industry Position: 20.1% below the Healthcare Providers & Services median (#193 of 512)
No single metric tells the full story. See the GDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
70GF Score
Get the complete analysis for GDRX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDRX has been successfully added to your 
